Date: 2015-06-30
Type of information: Initiation of development program
phase:
Announcement: initiation of development program
Company: Medivir (Sweden)
Product:
Action mechanism:
Disease: hepatocellular carcinoma
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On June 30, 2015, Medivir announced a new discovery project for a cancer indication, a liver targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC). The project is based on the company’s expertise in nucleoside and nucleotide science and is the first cancer project to emerge from its in-house discovery efforts in oncology that were announced in 2014.
